NeoMed makes first life science fund close

NeoMed Management, a Norway-based life sciences venture capital firm, has completed the first closing for its fourth fund at €38m ($50.3m).

The final fundraising target is €100m, which the firm expects to achieve by the summer.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump